Marathon Asset Management Ltd Raises Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Marathon Asset Management Ltd lifted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 3.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 279,203 shares of the company's stock after acquiring an additional 8,742 shares during the quarter. Marathon Asset Management Ltd owned 0.22% of Henry Schein worth $20,354,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of HSIC. Vanguard Group Inc. grew its stake in shares of Henry Schein by 1.7% during the first quarter. Vanguard Group Inc. now owns 15,432,001 shares of the company's stock worth $1,165,425,000 after purchasing an additional 260,537 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Henry Schein by 3.1% during the second quarter. American Century Companies Inc. now owns 5,484,286 shares of the company's stock worth $351,543,000 after purchasing an additional 162,477 shares in the last quarter. Swedbank AB acquired a new position in shares of Henry Schein during the first quarter worth $215,998,000. Nuance Investments LLC grew its stake in shares of Henry Schein by 6.2% during the second quarter. Nuance Investments LLC now owns 1,863,333 shares of the company's stock worth $119,440,000 after purchasing an additional 108,143 shares in the last quarter. Finally, Burgundy Asset Management Ltd. grew its stake in shares of Henry Schein by 1.0% during the second quarter. Burgundy Asset Management Ltd. now owns 1,640,379 shares of the company's stock worth $105,148,000 after purchasing an additional 16,476 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.

Insider Buying and Selling

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares of the company's stock, valued at $4,978,026.90. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.14% of the stock is currently owned by corporate insiders.

Henry Schein Stock Performance

Shares of HSIC traded up $0.72 during mid-day trading on Friday, hitting $72.39. 688,164 shares of the company's stock were exchanged, compared to its average volume of 1,335,087. Henry Schein, Inc. has a fifty-two week low of $60.01 and a fifty-two week high of $82.63. The firm has a market capitalization of $9.27 billion, a P/E ratio of 24.26, a P/E/G ratio of 1.98 and a beta of 0.86. The business's 50 day moving average is $70.33 and its two-hundred day moving average is $69.91. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.01. The business had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.27 billion. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The business's quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.31 earnings per share. On average, equities analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HSIC shares. Barrington Research reiterated an "outperform" rating and set a $82.00 target price on shares of Henry Schein in a research note on Friday, September 20th. Baird R W upgraded shares of Henry Schein from a "hold" rating to a "strong-buy" rating in a research note on Monday, July 22nd. Piper Sandler restated an "overweight" rating and issued a $86.00 price objective on shares of Henry Schein in a research note on Friday, June 21st. Evercore ISI upped their price objective on shares of Henry Schein from $70.00 to $74.00 and gave the company an "in-line" rating in a research note on Tuesday, October 8th. Finally, Robert W. Baird decreased their price objective on shares of Henry Schein from $92.00 to $82.00 and set an "outperform" rating for the company in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $77.50.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.